



Edgar Filing: BIOENVISION INC - Form 8-K

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

=====

=====

Item 7.01 Regulation FD Disclosure.

On February 8, 2005, Bioenvision, Inc. issued a press release announcing the closing of its previously announced underwritten public offering of common stock. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release dated February 8, 2005.

-2-

=====

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOENVISION, INC.

Dated: February 8, 2005

By: /s/ David P. Luci

-----

David P. Luci  
Chief Financial Officer, General Counsel  
and Corporate Secretary

-3-

EXHIBIT INDEX

Edgar Filing: BIOENVISION INC - Form 8-K

99.1 Press Release dated February 8, 2005.

-4-